Meta Information
ID:dasatinib-quercetin
Name:
Schema Version:AIM-2.0
Interactions
Target id:
/class/cyp3a4-strong-inhibitors
Target name:
Strong CYP3A4 Inhibitors
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Strong inhibitors of the CYP3A4 enzyme dramatically increase dasatinib levels in the blood, leading to a high risk of severe toxicity.
Actionable advice:
Avoid completely while using this combination.
Target id:
/dietary/grapefruit-pomelo
Target name:
Grapefruit or Grapefruit Juice
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Grapefruit is a potent inhibitor of the CYP3A4 enzyme, which can dangerously increase blood concentrations of dasatinib.
Actionable advice:
Avoid consuming grapefruit or its juice entirely.
Target id:
/class/broad-spectrum-inducers
Target name:
Strong CYP3A4 Inducers
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
These medications speed up the breakdown of dasatinib, drastically lowering its concentration and rendering it ineffective.
Actionable advice:
Avoid completely while using this combination.
Target id:
/intervention/saint-johns-wort
Target name:
Saint John's Wort
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
St. John's Wort is a powerful inducer of the CYP3A4 enzyme, which significantly reduces dasatinib levels and its senolytic effect.
Actionable advice:
Do not take St. John's Wort with this combination.
Target id:
/class/proton-pump-inhibitors
Target name:
Proton Pump Inhibitors (PPIs)
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
PPIs create a long-lasting reduction in stomach acid, which severely impairs the absorption of dasatinib.
Actionable advice:
Avoid using PPIs completely with this therapy.
Target id:
/class/anticoagulants-antiplatelets
Target name:
Anticoagulants and Antiplatelets
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Both dasatinib and quercetin can inhibit platelet function, and combining them with blood thinners creates a very high risk of serious bleeding.
Actionable advice:
This combination is contraindicated; avoid completely.
Target id:
/class/qt-prolonging-agents
Target name:
QT-Prolonging Medications
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Dasatinib can prolong the QT interval of the heart; taking it with other drugs that do the same increases the risk of a life-threatening cardiac arrhythmia.
Actionable advice:
Avoid co-administration with any other QT-prolonging drugs.
Target id:
/condition/qt-prolongation
Target name:
History of QT Prolongation
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Individuals with a personal or family history of Long QT Syndrome are at a significantly higher risk of dangerous cardiac arrhythmias from dasatinib.
Actionable advice:
This therapy is contraindicated for individuals with this condition.
Target id:
/condition/bleeding-disorders
Target name:
Bleeding Disorders
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The antiplatelet effects of both dasatinib and quercetin pose a significant risk of severe bleeding in individuals with pre-existing bleeding disorders.
Actionable advice:
Do not use this combination if you have a bleeding disorder.
Target id:
/condition/hepatic-impairment
Target name:
Liver Impairment
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Dasatinib is extensively metabolized by the liver; impaired liver function can lead to dangerously high drug levels and toxicity.
Actionable advice:
Avoid this therapy if you have moderate to severe liver disease.
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Dasatinib can cause fetal harm and is strictly contraindicated during pregnancy.
Actionable advice:
Do not use this combination if you are pregnant or may become pregnant.
Target id:
/condition/lactation
Target name:
Breastfeeding
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is not known if dasatinib or quercetin pass into breast milk, but due to the potential for serious adverse reactions in the infant, it is contraindicated.
Actionable advice:
Do not use this combination while breastfeeding.
Target id:
/class/h2-receptor-antagonists
Target name:
H2 Receptor Antagonists (H2 Blockers)
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
10
Hours after target:
2
Description:
H2 blockers reduce stomach acid needed for dasatinib absorption. Proper timing is required to separate the doses and minimize this interaction.
Actionable advice:
Take dasatinib-quercetin at least 2 hours before or 10 hours after taking an H2 blocker.
Target id:
/class/antacids
Target name:
Antacids
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
Antacids neutralize stomach acid, which can significantly reduce the absorption of dasatinib if taken at the same time.
Actionable advice:
Separate doses by at least 2 hours before or after taking an antacid.
Target id:
/class/nsaids
Target name:
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
NSAIDs increase the risk of gastrointestinal bleeding and also have antiplatelet effects, which are additive with dasatinib and quercetin.
Actionable advice:
Avoid using NSAIDs while on this therapy to minimize bleeding risk.
Target id:
/class/statins
Target name:
Statins (HMG-CoA Reductase Inhibitors)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Dasatinib can increase the concentration of some statins (like simvastatin and atorvastatin), increasing the risk of muscle-related side effects (myopathy).
Actionable advice:
Avoid co-administration, or use a statin not metabolized by CYP3A4 (e.g., pravastatin, rosuvastatin) with caution.
Target id:
/condition/heart-failure
Target name:
Heart Failure
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Dasatinib can cause fluid retention, which may worsen symptoms in patients with heart failure.
Actionable advice:
Use with extreme caution or avoid in individuals with a history of heart failure.
Target id:
/condition/renal-impairment
Target name:
Renal Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
While dasatinib is not cleared by the kidneys, very high doses of quercetin have been associated with kidney toxicity in some studies.
Actionable advice:
Use with caution in mild-to-moderate renal impairment and avoid in severe cases.
Target id:
/procedure/elective-surgery
Target name:
Elective Surgery
Severity:
major
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
168
Hours after target:
null
Description:
Due to the significant risk of increased bleeding from antiplatelet effects, this combination must be stopped well in advance of any surgical procedure.
Actionable advice:
Discontinue this therapy at least 7 days prior to any scheduled surgery.
Target id:
/dietary/meal
Target name:
Meal (especially with fat)
Severity:
moderate
Interaction type:
requirement
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Taking this combination with food, particularly a meal containing some fat, can enhance the absorption of quercetin and ensure consistent absorption of dasatinib.
Actionable advice:
Always take this combination with a meal.
Target id:
/intervention/dasatinib
Target name:
Dasatinib (Self-Interaction)
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Quercetin moderately inhibits the CYP3A4 enzyme, which increases the concentration and bioavailability of the co-administered dasatinib, enhancing its effects but also its potential side effects.
Actionable advice:
Be aware that quercetin amplifies dasatinib's effects and risks; do not take them separately.
Target id:
/class/chelating-minerals
Target name:
Chelating Minerals (Iron, Zinc)
Severity:
minor
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
Quercetin can bind to minerals like iron and zinc in the gut, which may reduce their absorption if taken at the same time.
Actionable advice:
Separate mineral supplements by at least 2 hours from your dasatinib-quercetin dose.
Target id:
/biomarker/complete-blood-count
Target name:
Complete Blood Count (CBC)
Severity:
major
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
Dasatinib can cause myelosuppression, leading to low blood cell counts (anemia, neutropenia, thrombocytopenia), which requires regular monitoring.
Actionable advice:
Regular blood count monitoring is required before and during therapy.
Target id:
/biomarker/comprehensive-liver-function-panel
Target name:
Liver Function Panel
Severity:
major
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
As dasatinib is metabolized by the liver, monitoring liver enzymes is essential to detect potential hepatotoxicity.
Actionable advice:
Regular liver function tests are required before and during therapy.
Target id:
/biomarker/serum-potassium
Target name:
Serum Potassium & Magnesium
Severity:
major
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
Electrolyte imbalances, particularly low potassium or magnesium, increase the risk of dasatinib-induced QT prolongation and cardiac arrhythmias.
Actionable advice:
Ensure potassium and magnesium levels are checked and corrected before starting therapy.